Advertisement

The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis

  • Liangfeng ChenEmail author
  • Xiaobing Han
  • Zhongzhou Hu
  • Liangxin Chen
Original Article
  • 44 Downloads

Abstract

Purpose

The efficacy of cisplatin-based chemotherapy remains an open question for chemo-resistance in non-small cell lung cancer (NSCLC). This study aimed to explore the role and mechanism of long noncoding RNA plasmacytoma variant translocation 1 (PVT1) in cisplatin sensitivity of NSCLC.

Methods

Paired tumor and adjacent tissues were collected from forty patients with NSCLC. The clinical value of PVT1 was investigated according to clinicopathological parameters of patients. Cisplatin-sensitive or -resistant cells (A549 or A549/DDP) were used for in vitro experiments. Cell viability, apoptosis, autophagy and animal experiments were conducted to investigate cisplatin sensitivity. The expressions of PVT1, microRNA-216b (miR-216b) and apoptosis- or autophagy-related proteins were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) or western blot assay, respectively. Luciferase reporter assay and RNA immunoprecipitation (RIP) assay were conducted to probe the interaction between miR-216b and PVT1 or Beclin-1.

Results

PVT1 was highly expressed and associated with poor prognosis of NSCLC patients (*P < 0.05). PVT1 knockdown enhanced cisplatin-induced viability inhibition and apoptosis induction in A549/DDP cells, but addition of PVT1 caused an opposite effect in A549 cells (*P < 0.05, #P < 0.05). Moreover, accumulation of PVT1 facilitated autophagy of NSCLC cells and tumor growth in vivo (*P < 0.05, #P < 0.05). In addition, miR-216b interacted with PVT1 or Beclin-1. Beclin-1 reversed miR-216b-mediated effect on autophagy and apoptosis of NSCLC cells (*P < 0.05,#P < 0.05). Besides, Beclin-1 protein expression was regulated by PVT1 and miR-216b (*P < 0.05, #P < 0.05).

Conclusions

PVT1 may function as a competing endogenous RNA for miR-216b to inhibit cisplatin sensitivity of NSCLC through regulating apoptosis and autophagy via miR-216b/Beclin-1 pathway, providing a novel target for improving chemo-therapy efficacy of NSCLC.

Keywords

PVT1 NSCLC Cisplatin sensitivity Autophagy miR-216b Beclin-1 

Notes

Author contributions

LC designed and performed the experiments, wrote the manuscript. XH and ZH contributed to experimental work and data analysis. LC and LC conducted the experiments and revised the manuscript. All authors have read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

Author Liangfeng Chen declares that he has no conflict of interest. Author Xiaobing Han declares that she has no conflict of interest. Author Zhongzhou Hu declares that he has no conflict of interest. Author Liangxin Chen declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All animal experiments were performed in accordance with the Guidelines for Care and Use of Laboratory Animal.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Siegel R, Miller K, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang H (2015) Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther 9:6075–6081CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J, Zhu J, Johnson D (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98CrossRefPubMedGoogle Scholar
  4. 4.
    Hu Y, Zhu Q, Deng J, Li Z, Wang G, Zhu Y (2018) Emerging role of long non-coding RNAs in cisplatin resistance. Onco Targets Ther 11:3185–3194CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wang L, Ma L, Xu F, Zhai W, Dong S, Yin L, Liu J, Yu Z (2018) Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer 9(7):761–768CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Liu E, Liu Z, Zhou Y, Mi R, Wang D (2015) Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med 8(11):20565–20572PubMedPubMedCentralGoogle Scholar
  7. 7.
    Zhang X, Bu P, Liu L, Zhang X, Li J (2015) Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun 462(3):227–232CrossRefPubMedGoogle Scholar
  8. 8.
    Ping G, Xiong W, Zhang L, Li Y, Zhang Y, Zhao Y (2018) Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res 10(1):138–149PubMedPubMedCentralGoogle Scholar
  9. 9.
    Wu D, Li Y, Zhang H, Hu X (2017) Knockdown of Lncrna PVT1 enhances radiosensitivity in non-small cell lung cancer by sponging Mir-195. Cell Physiol Biochem 42(6):2453–2466CrossRefPubMedGoogle Scholar
  10. 10.
    Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I (2011) A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147(2):358–369CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zang H, Peng J, Wang W, Fan S (2017) Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. J Cancer 8(18):3856–3861CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Liu S, Dong H, Dai H, Liu D, Wang Z (2018) MicroRNA-216b regulated proliferation and invasion of non-small cell lung cancer by targeting SOX9. Oncol Lett 15(6):10077–10083PubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu Y, Niu Z, Lin X, Tian Y (2017) MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Cancer Gene Ther 24(5):208–214CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang Y, Yang W, Zhu H, Qian Y, Zhou L, Ren Y, Ren X, Zhang L, Liu X, Liu C, Ming Z, Li B, Chen B, Wang J, Liu Y, Yang J (2014) Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. Biochem Pharmacol 87(4):562–570CrossRefPubMedGoogle Scholar
  15. 15.
    Wang X, Du Z, Li L, Shi M, Yu Y (2015) Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome. Int J Clin Exp Pathol 8(9):10644–10652PubMedPubMedCentralGoogle Scholar
  16. 16.
    Guo D, Wang Y, Ren K, Han X (2018) Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression. Exp Cell Res 362(1):172–179CrossRefPubMedGoogle Scholar
  17. 17.
    Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader J (2016) The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis. PLoS One 11(5):e0156274CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kasprowska-Liśkiewicz D (2017) The cell on the edge of life and death: crosstalk between autophagy and apoptosis. Postepy Hig Med Dosw 71(0):825–841Google Scholar
  19. 19.
    Liu G, Pei F, Yang F, Li L, Amin A, Liu S, Buchan J, Cho W (2017) Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci 18(2):367CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Kaushal G, Kaushal V, Herzog C, Yang C (2008) Autophagy delays apoptosis in renal tubular epithelial cells in cisplatin cytotoxicity. Autophagy 4(5):710–712CrossRefPubMedGoogle Scholar
  21. 21.
    Sun W, Zu Y, Fu X, Deng Y (2017) Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep 38(6):3347–3354PubMedPubMedCentralGoogle Scholar
  22. 22.
    Liz J, Esteller M (2016) lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta 1859(1):169–176CrossRefPubMedGoogle Scholar
  23. 23.
    Yuan P, Cao W, Zang Q, Li G, Guo X, Fan J (2016) The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy. Biochem Biophys Res Commun 478(3):1067–1073CrossRefPubMedGoogle Scholar
  24. 24.
    Huang G, Pan J, Ye Z, Fang B, Cheng W, Cao Z (2017) Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget 8(61):104206–104215PubMedPubMedCentralGoogle Scholar
  25. 25.
    Ma Y, Wang P, Xue Y, Qu C, Zheng J, Liu X, Ma J, Liu Y (2017) PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186. Tumour Biol 39(3):1010428317694326PubMedGoogle Scholar
  26. 26.
    Xu X, Fu Y, Tong J, Fan S, Xu K, Sun H, Liang Y, Yan C, Yuan Z, Ge Y (2014) MicroRNA-216b/Beclin 1 axis regulates autophagy and apoptosis in human Tenon’s capsule fibroblasts upon hydroxycamptothecin exposure. Exp Eye Res 123:43–55CrossRefPubMedGoogle Scholar
  27. 27.
    Zou Z, Wu L, Ding H, Wang Y, Zhang Y, Chen X, Chen X, Zhang C, Zhang Q, Zen K (2012) MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 287(6):4148–4156CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang Y, Meng X, Li C, Tan Z, Guo X, Zhang Z, Xi T (2017) MiR-9 enhances the sensitivity of A549 cells to cisplatin by inhibiting autophagy. Biotechnol Lett 39(7):959–966CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of OncologyXinyang Central HospitalXinyangChina

Personalised recommendations